Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight

The alcohol use disorder (AUD) market is projected to grow at a 12.1% CAGR from 2026-2036, driven by novel therapeutic mechanisms and new drug approvals. The market was valued at USD 1.1 billion in 2025 across seven major markets. Key emerging therapies from companies like Adial Pharmaceuticals, Eli Lilly, MediciNova, and Altimmune are expected to transform the treatment landscape, with AD04 projected to capture the largest market share by 2036, replacing current leader VIVITROL.

06/08/2026, 1:00 PM • GlobeNewswire

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake

Commodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expected. The exit suggests the fund may be taking profits after the strong rally or reallocating capital to other clinical-stage biotech names.

02/23/2026, 10:26 AM • The Motley Fool

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million

Commodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.

02/23/2026, 10:18 AM • The Motley Fool

Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing

The Irish High Court has sanctioned Avadel Pharmaceuticals' scheme of arrangement without modification, allowing Alkermes to acquire Avadel's entire issued share capital. The transaction is expected to close on February 12, 2026, with trading of Avadel shares on Nasdaq halting on February 11, 2026.

02/10/2026, 4:05 PM • Benzinga

Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes

Avadel Pharmaceuticals shareholders have approved the proposed acquisition by Alkermes plc through a scheme of arrangement. The approval was overwhelming, with 97.41% of votes cast in favor at the scheme meeting and 96.53% approval at the extraordinary general meeting. The transaction is expected to proceed pending satisfaction of remaining conditions.

01/12/2026, 4:05 PM • Benzinga

Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting

Avadel Pharmaceuticals announced the mailing of a proxy statement regarding its proposed acquisition by Alkermes, with scheme and extraordinary general meetings scheduled for January 12, 2026, to vote on the transaction.

12/03/2025, 4:47 PM • Benzinga

Deal Dispatch: From Four Roses Bourbon To Quantum Stakes, Here Are This Week's Sector Shake Ups

Multiple corporate deals and strategic investments highlighted this week, including Kirin's potential Four Roses acquisition, quantum computing companies seeking U.S. government equity stakes, and Six Flags attracting activist investor interest with Travis Kelce's involvement.

10/24/2025, 12:20 PM • Benzinga

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avadel Pharmaceuticals plc (NASDAQ: AVDL)

Law firm Monteverde & Associates is investigating the proposed sale of Avadel Pharmaceuticals to Alkermes, where shareholders will receive $18.50 per share plus a potential additional $1.50 contingent on FDA approval of LUMRYZ™ by end of 2028.

10/22/2025, 5:30 PM • Benzinga

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

Alkermes agreed to acquire Avadel Pharmaceuticals for up to $20 per share, valuing the deal at $2.1 billion. The acquisition includes the narcolepsy drug Lumryz and is expected to close in Q1 2026, with potential additional payment contingent on FDA approval.

10/22/2025, 3:18 PM • Benzinga